The current financial score of Eton Pharmaceuticals Inc is 8.40. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 37.59M, representing a year-over-year increase of 98.59%, while its net profit experienced a year-over-year increase of 547.89%.
The current valuation score of Eton Pharmaceuticals Inc is 9.28. Its current P/E ratio is -1000.72, which is -110.34% below the recent high of 103.51 and -15.86% above the recent low of -1159.44.
The current earnings forecast score of Eton Pharmaceuticals Inc is 8.00. The average price target is 67.50, with a high of 70.00 and a low of 62.00.
The current price momentum score of Eton Pharmaceuticals Inc is 3.63. Currently, the stock price is trading between the resistance level at 61.61 and the support level at 51.61, making it suitable for range-bound swing trading.
The current institutional shareholding score of Eton Pharmaceuticals Inc is 5.00. The latest institutional shareholding proportion is 58.43%, representing a quarter-over-quarter decrease of 4.32%. The largest institutional shareholder is James Simons, holding a total of 52.30K shares, representing 0.00% of shares outstanding, with 51.57% decrease in holdings.
The current risk assessment score of Eton Pharmaceuticals Inc is 5.41. The company's beta value is 0.88. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.